Detection of PKC-iota as a Biomarker for Brain Tumorigenesis
AssigneeUniversity of South Florida
InventorsMildred Acevedo-Duncan, Rekha Patel
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of South Florida
InventorsMildred Acevedo-Duncan, Rekha Patel
Estimating the term…
A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.
A method of detecting brain tumorigenesis in a subject comprising the steps of:
A method of diagnosing the presence of a glioma or meningioma in a subject, comprising:
A diagnostic kit for the detection of brain tumorigenesis comprising in combination:
A method of treating a brain tumor in a subject comprising the step of administering to the subject a compound that inhibits the expression of PKC-iota.
A method of inhibiting expression of human PKC-iota mRNA comprising administering to a subject an effective amount of an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence substantially identical to a target sequence of about 19 to about 25 contiguous nucleotides in human PKC-iota mRNA such that the human PKC-iota mRNA is degraded.
The method of claim 17, wherein the siRNA is administered in conjunction with a delivery reagent.
A method of detecting brain tumorigenesis in a subject comprising the steps of:
Dependencies are inferred from the claim text.